Arcutis (ARQT) CFO sells 1,320 shares to cover RSU tax withholding

Rhea-AI Filing Summary

Arcutis Biotherapeutics SVP CFO Latha Vairavan reported a small insider sale tied to equity compensation. On February 2, 2026, she sold 1,320 shares of common stock at a weighted average price of $25.4984 per share. According to the footnotes, the sale was made solely to cover tax withholding obligations arising from the vesting of previously granted restricted stock units. Following this transaction, she beneficially owns 63,607 shares of Arcutis common stock directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vairavan Latha

(Last) (First) (Middle)

C/O ARCUTIS BIOTHERAPEUTICS, INC.

3027 TOWNSGATE ROAD, SUITE 300

(Street)

WESTLAKE VILLAGE CA 91361

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Arcutis Biotherapeutics, Inc. [ ARQT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/02/2026		S(1)		1,320	D	$25.4984(2)	63,607	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligation in connection with the vesting of Restricted Stock Units ("RSUs"), granted on January 12, 2024, in which 25% of the RSUs vest annually on February 1, (the "Vesting Commencement Date"), of each year beginning on February 1, 2025, subject to the Reporting Person's continued service to the Issuer.

2. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.745 to $25.68, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Remarks:

	/s/ Masaru Matsuda, as Attorney-in-Fact for Latha Vairavan	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Arcutis Biotherapeutics (ARQT) report for its CFO?

Arcutis Biotherapeutics reported that SVP Chief Financial Officer Latha Vairavan sold 1,320 shares of common stock. The transaction was disclosed on Form 4 and is described as a sale to cover tax withholding obligations related to vesting restricted stock units.

When did the Arcutis (ARQT) CFO’s 1,320-share sale occur and at what price?

The sale occurred on February 2, 2026, at a weighted average price of $25.4984 per share. The Form 4 notes the shares were sold in multiple trades within a price range of $24.745 to $25.68, yielding the reported average price.

How many Arcutis (ARQT) shares does CFO Latha Vairavan own after this Form 4 transaction?

After selling 1,320 shares, CFO Latha Vairavan beneficially owns 63,607 shares of Arcutis common stock. The filing lists these shares as directly held, reflecting her remaining equity stake following the tax-related sale linked to vesting restricted stock units.

Why did the Arcutis (ARQT) CFO sell 1,320 shares according to the Form 4 footnotes?

The footnotes explain the sale represents shares sold to cover tax withholding obligations from vesting restricted stock units. These RSUs were granted on January 12, 2024 and vest 25% annually starting February 1, 2025, conditioned on continued service with Arcutis Biotherapeutics.

What does the Form 4 say about the pricing of the Arcutis (ARQT) CFO’s share sale?

The Form 4 states the reported $25.4984 price is a weighted average. Shares were sold in multiple transactions at prices between $24.745 and $25.68. The reporting person undertakes to provide detailed trade breakdowns upon request to regulators, the issuer, or shareholders.